PABEFA Trademark
Trademark Overview
On Tuesday, October 8, 2019, a trademark application was filed for PABEFA with the United States Patent and Trademark Office. The USPTO has given the PABEFA trademark a serial number of 79273365. The federal status of this trademark filing is REGISTERED as of Tuesday, May 5, 2020. This trademark is owned by Glaxo Group Limited. The PABEFA trademark is filed in the Pharmaceutical Products category with the following description:
Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; vaccines
General Information
| Serial Number | 79273365 |
| Word Mark | PABEFA |
| Filing Date | Tuesday, October 8, 2019 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, May 5, 2020 |
| Registration Number | 6044757 |
| Registration Date | Tuesday, May 5, 2020 |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, February 18, 2020 |
Trademark Statements
| Goods and Services | Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; vaccines |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Tuesday, December 17, 2019 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Glaxo Group Limited |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Party Name | Glaxo Group Limited |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | GB |
| Party Name | Glaxo Group Limited |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | GB |
Trademark Events
| Event Date | Event Description |
| Thursday, December 5, 2019 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Monday, December 16, 2019 | LIMITATION FROM ORIGINAL APPLICATION ENTERED |
| Saturday, December 21, 2019 | APPLICATION FILING RECEIPT MAILED |
| Monday, January 13, 2020 | ASSIGNED TO EXAMINER |
| Tuesday, January 14, 2020 | ASSIGNED TO LIE |
| Wednesday, January 29, 2020 | NOTICE OF PUBLICATION |
| Tuesday, February 18, 2020 | PUBLISHED FOR OPPOSITION |
| Tuesday, May 5, 2020 | REGISTERED-PRINCIPAL REGISTER |
| Thursday, June 4, 2020 | GRANT OF PROTECTION CREATED, TO BE SENT TO IB |
| Wednesday, July 8, 2020 | FINAL DISPOSITION PROCESSED |
| Wednesday, July 8, 2020 | FINAL DISPOSITION NOTICE SENT TO IB |
| Tuesday, December 17, 2019 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, January 13, 2020 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, July 24, 2020 | NOTIFICATION PROCESSED BY IB |
| Friday, August 11, 2023 | CHANGE OF NAME/ADDRESS REC'D FROM IB |
| Friday, May 30, 2025 | NEW REPRESENTATIVE AT IB RECEIVED |
